An2 Therapeutics Stock Analysis

AN2 Stock Analysis Notes

About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.46. Some equities with similar Price to Book (P/B) outperform the market in the long run. AN2 Therapeutics recorded a loss per share of 1.99. The entity last dividend was issued on the 11th of January 2018. AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. An2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. For more info on AN2 Therapeutics please contact Eric Easom at 650 331 9090 or go to https://www.an2therapeutics.com.

AN2 Therapeutics Investment Alerts

AN2 Therapeutics Upcoming and Recent Events

AN2 Largest EPS Surprises

View All Earnings Estimates

AN2 Therapeutics Thematic Classifications

AN2 Stock Institutional Investors

Note, although AN2 Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

AN2 Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.04 M.

AN2 Profitablity

Management Efficiency

AN2 Therapeutics has return on total asset (ROA) of (0.4289) % which means that it has lost $0.4289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6948) %, meaning that it created substantial loss on money invested by shareholders. AN2 Therapeutics' management efficiency ratios could be used to measure how well AN2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2024. Return On Capital Employed is likely to drop to -0.59 in 2024. At this time, AN2 Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.6 M in 2024, whereas Total Assets are likely to drop slightly above 69.6 M in 2024.

Technical Drivers

As of the 25th of November, AN2 Therapeutics owns the Market Risk Adjusted Performance of 0.476, standard deviation of 3.62, and Coefficient Of Variation of 1047.82. AN2 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.

AN2 Therapeutics Price Movement Analysis

AN2 Therapeutics Insider Trading Activities

AN2 Therapeutics Predictive Daily Indicators

AN2 Therapeutics Forecast Models

AN2 Therapeutics' time-series forecasting models are one of many AN2 Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AN2 Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how AN2 Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling AN2 shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as AN2 Therapeutics. By using and applying AN2 Stock analysis, traders can create a robust methodology for identifying AN2 entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. AN2 analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. AN2 analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

AN2 Therapeutics stock analysis indicators help investors evaluate how AN2 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading AN2 Therapeutics shares will generate the highest return on investment. By understating and applying AN2 Therapeutics stock analysis, traders can identify AN2 Therapeutics position entry and exit signals to maximize returns.

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.